Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study

被引：4

作者：

Lalanne, Sebastien ^{[1
,2
]}

Jezequel, Caroline ^{[3
]}

Tron, Camille ^{[1
,2
]}

Verdier, Marie-Clemente ^{[1
,2
]}

Mercerolle, Marion ^{[4
]}

Pronier, Charlotte ^{[5
]}

Guyader, Dominique ^{[2
,3
]}

Lemaitre, Florian ^{[1
,2
]}

机构：

[1] Rennes Univ Hosp, Fac Med, Dept Biol & Clin Pharmacol, Rennes, France

[2] Inserm, CIC P Clin Invest Ctr 1414, Rennes, France

[3] Rennes Univ Hosp, Liver Dis Unit, Rennes, France

[4] Rennes Univ Hosp, Dept Pharm, Rennes, France

[5] Rennes Univ Hosp, Dept Virol, Rennes, France

来源：

THERAPEUTIC DRUG MONITORING | 2020年 / 42卷 / 02期

关键词：

sofosbuvir; velpatasvir; crushing; pharmacokinetics; exposure;

D O I：

10.1097/FTD.0000000000000718

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure.

引用

页码：163 / 164

页数：2

共 50 条

[41] Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle
Mitrev, N.
Kariyawasam, V.
Leong, R. W.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (09) : 1279 - 1280
[42] Sofosbuvir/Velpatasvir for the Treatment of HCV in Patients with Decompensated Liver Disease: The ASTRAL-4 Study
Charlton, M.
O'Leary, J.
Osinusi, A.
Brainard, D. M.
McHutchison, J. G.
Brown, R. S.
Curry, M.
TRANSPLANTATION, 2016, 100 : S102 - S103
[43] Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)
Mitrev, N.
Vande Casteele, N.
Seow, C.
Andrews, J. M.
Connor, S. J.
Moore, G.
Barclay, M.
Begun, J.
Bryant, R.
Chan, W.
Corte, C.
Ghaly, S.
Lemberg, D. A.
Kariyawasam, V.
Lewindon, P.
Martin, J.
Mountifield, R.
Radford-Smith, G.
Slobodian, P.
Sparrow, M.
Toong, C.
Van Langenberg, D.
Ward, M. G.
Leong, R. W.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 136 - 138
[44] Methadone/sofosbuvir/velpatasvir/tamsulosin interactionFacial and bilateral lower extremity oedema following drug interaction: case report
Reactions Weekly, 2020, 1822 (1) : 193 - 193
[45] Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
Brochot, Etienne
Bodeau, Sandra
Duverlie, Gilles
THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 550 - 551
[46] Therapeutic Drug Monitoring for Antidepressant Drug Treatment
Haji, Elnaz Ostad
Hiemke, Christoph
Pfuhlmann, Bruno
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (36) : 5818 - 5827
[47] Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
C. Louwrens Braal
Anne Kleijburg
Agnes Jager
Stijn L. W. Koolen
Ron H. J. Mathijssen
Isaac Corro Ramos
Pim Wetzelaer
Carin A. Uyl-de Groot
Clinical Drug Investigation, 2022, 42 : 163 - 175
[48] Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
Braal, C. Louwrens
Kleijburg, Anne
Jager, Agnes
Koolen, Stijn L. W.
Mathijssen, Ron H. J.
Ramos, Isaac Corro
Wetzelaer, Pim
Uyl-de Groot, Carin A.
CLINICAL DRUG INVESTIGATION, 2022, 42 (02) : 163 - 175
[49] Posaconazole: The Case for Therapeutic Drug Monitoring
Howard, Susan J.
Felton, Timothy W.
Gomez-Lopez, Alicia
Hope, William W.
THERAPEUTIC DRUG MONITORING, 2012, 34 (01) : 72 - 76
[50] Therapeutic drug monitoring in the treatment of tuberculosis
Peloquin, CA
DRUGS, 2002, 62 (15) : 2169 - 2183

← 1 2 3 4 5 →